Key Highlights

  • Shares fell 7.55% in pre-market trading to $8.70, down from a prior close of $9.41
  • Second quarter Revenue of $318,000 missed the $886,300 consensus estimate by more than 64%
  • Adjusted loss per share of $0.21 missed the $0.15 estimate
  • Completed a $100 million underwritten offering, including a $40 million strategic Investment from Eli Lilly
  • Reported positive interim Phase 1 data for ABS-201, its lead pattern hair loss candidate
  • Cash, cash equivalents, and marketable securities of $201.1 million as of June 30, 2026, expected to fund operations into the second half of 2028

Revenue Miss and New Offering Outweigh Positive Trial Data

Absci (NASDAQ:ABSI) shares were trading at $8.70 in pre-market activity on August 12, 2026, down 7.55% from the prior close of $9.41. Shares had gained 4.44% during the prior regular session, but slid in extended and pre-market trading as investors weighed the company's second quarter 2026 financial results against a new Capital raise.

Revenue for the quarter came in at just $318,000, missing the $886,300 consensus estimate by more than 64%, and adjusted loss per share of $0.21 missed the $0.15 estimate. The company also completed a $100 million underwritten offering in June, including a $40 million strategic Equity investment from Eli Lilly (NYSE:LLY), which also gained a seat on Absci's Endometriosis Advisory Board as part of the arrangement. Investors appear to be weighing the encouraging clinical progress and extended cash runway into the second half of 2028 against the steep revenue shortfall and widening net loss of $33.2 million for the quarter.

What Absci Does

Absci is a Vancouver, Washington based clinical-stage biopharmaceutical company advancing therapeutics designed with generative AI. Its Integrated Drug Creation platform combines AI models with a synthetic biology data engine to enable rapid design of therapeutics, with a continuous feedback loop between algorithms and wet lab validation. The company's lead candidate, ABS-201, is being developed for both pattern hair loss and endometriosis, conditions the company has framed as reflecting a combined multibillion-dollar market opportunity.

Positive ABS-201 Data Failed to Offset the Financial Miss

Founder and Chief Executive Officer Sean McClain said the positive Phase 1 interim data from the HEADLINE trial, combined with the company's strengthened Balance Sheet and advancing platform, position the company well going forward. Blinded, aggregate interim data suggested ABS-201 was well tolerated with a favorable safety profile, and an estimated half-life of at least 65 days supports the potential for dosing just two or three times over six months. The company anticipates interim proof-of-concept data for pattern hair loss later in 2026, with full 26-week data expected in early 2027, and plans to begin a Phase 2 trial in endometriosis in the fourth quarter of 2026.

Conclusion

Absci's pre-market decline reflects a financial results miss and the dilutive impact of a recent capital raise outweighing genuinely positive early clinical data for its lead candidate. With cash now extended into the second half of 2028 and key proof-of-concept readouts for both pattern hair loss and endometriosis still ahead, the company's near-term share price pressure does not necessarily reflect a change in its underlying clinical trajectory.